Surface Oncology, Inc. Common Stock
SURF
SURF was delisted on the 7th of September, 2023.
50 hedge funds and large institutions have $70.5M invested in Surface Oncology, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 9 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
156% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 9
16% more funds holding
Funds holding: 43 → 50 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
63% less capital invested
Capital invested by funds: $191M → $70.5M (-$121M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$6.93M |
| 2 |
BlackRock
New York
|
+$3.83M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$766K |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$708K |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
+$644K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.9M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$5.25M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.81M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.93M |
| 5 |
Millennium Management
New York
|
-$1.56M |
SURF Hedge Fund Activity: Q4 2018 in Review
50 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q4 2018, worth a combined $70.5M — down 63% from $191M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new SURF positions and 4 closed out — a net gain of 7 holders — while 23 added to existing stakes and 9 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $6.93M. The largest seller was Fidelity Investments, cutting an estimated $12.9M.
- 50 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q4 2018, up from 43 in Q3 2018.
- Funds reported $70.5M of Surface Oncology, Inc. Common Stock stock for Q4 2018, down 63% quarter-over-quarter.
- 11 funds opened new Surface Oncology, Inc. Common Stock positions in Q4 2018 and 4 closed out, a net change of +7 holders.
- The largest Surface Oncology, Inc. Common Stock buyer in Q4 2018 was EcoR1 Capital, an estimated $6.93M added.
- The largest Surface Oncology, Inc. Common Stock seller in Q4 2018 was Fidelity Investments, an estimated $12.9M sold.
Based on aggregated 13F filings for Q4 2018.